Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@inspirna.com

Overview

Impact

Inspirna has multiple therapies in development for the treatment of difficult to treat cancers.

Our proprietary RNA-DRIVEr™ platform has revealed multiple critical drivers that can be drugged by novel small molecule and biologic therapeutics that represent first-in-class or best-in-class drug candidates. 

These novel drug candidates are being developed in clinical settings of high unmet medical need, including colorectal cancer (RGX-202) as well as small cell lung cancer and non-small cell lung cancer (RGX-104), for the treatment of patients that harbor target biomarkers that have been associated with clinical activity in completed Phase 1a studies.

Current status of programs

Pipeline

RGX-202

RGX-202 is an oral small molecule inhibitor of SLC6A8 that induces apoptosis (cell death) of colorectal cancer cells.

Pipeline

Abequolixron (RGX-104)

RGX-104 is an oral small molecule activator of LXR/APOE that inhibits the growth of tumor blood vessels (angiogenesis) and activates tumor myeloid cells to enhance the immune response against tumors.

Pipeline

RGX-019

RGX-019 is a monoclonal antibody-drug conjugate (ADC) that targets MERTK to selectivity kill cancer cells and activate tumor myeloid cells.